Designing the next era of transcatheter care.

1. Clinical foundation

In nonvalvular atrial fibrillation, thrombus frequently originates in the left atrial appendage. Percutaneous LAA closure mechanically excludes this trabeculated, low-flow chamber from the systemic circulation. The therapeutic trade is deliberate: accept an up-front invasive procedure and a period of device healing to reduce long-term dependence on oral anticoagulation.

2. Patient selection and indications

Best-aligned clinical profile

• Nonvalvular AF with meaningful thromboembolic risk and a rationale to avoid indefinite oral anticoagulation.
• Prior major bleeding, clinically important recurrent bleeding, or a high-risk condition that makes future bleeding likely.
• Inability to maintain safe anticoagulation because of falls, frailty, occupational risk, adherence barriers, drug interaction, renal dysfunction, or intolerance—after reversible causes are addressed.
• Ability to complete at least a short post-implant antithrombotic regimen and surveillance imaging.

Do not reduce selection to a score

CHA₂DS₂-VASc estimates thromboembolic risk and HAS-BLED helps reveal modifiable bleeding hazards, but neither substitutes for judgment. Document the bleeding phenotype, its reversibility, expected anticoagulant exposure, life expectancy, frailty, competing stroke mechanisms, and the patient’s goals.

3. Anatomy and transseptal strategy

The LAA ostium lies anterolateral to the left superior pulmonary vein and superior to the mitral annulus, with the left circumflex artery and great cardiac vein along its inferior epicardial relationship. Chicken-wing, windsock, cactus, and cauliflower labels are descriptive—not procedural endpoints. What matters is the ostial plane, landing-zone diameter, depth, angulation, lobes, trabeculation, proximal ridge, and relationship to the pulmonary vein and mitral apparatus.

Transseptal puncture is part of device sizing

The puncture determines coaxiality, sheath torque, depth, and deployment force. A posterior-inferior puncture is frequently favorable, but the ideal site is anatomy- and device-specific. Use bicaval and short-axis TEE views, confirm tenting, and assess the trajectory before crossing. An anterior puncture can force oblique deployment; an excessively superior puncture can reduce working depth.

4. Pre-procedural TEE and cardiac CT

TEE acquisition

Interrogate the LAA near 0°, 45°, 90°, and 135° with deliberate gain and depth optimization. Identify thrombus versus spontaneous echo contrast, measure the ostium and intended landing zone, define maximum diameter and usable depth, evaluate lobes, document baseline pericardial space, and inspect the interatrial septum.

CT acquisition and reconstruction

Use ECG-gated cardiac CT with adequate left-atrial opacification; a delayed phase helps distinguish slow flow from thrombus. Reconstruct the ostial plane orthogonal to the LAA axis and measure minimum and maximum diameters, perimeter, area, depth, and morphology. CT often reveals a larger maximal dimension than 2-D TEE because the landing zone is elliptical.

5. Implant procedure: a disciplined sequence

1. Team brief and imaging reviewConfirm indication, therapy plan, thrombus exclusion, device strategy, access, anesthesia, renal plan, and rescue equipment.
2. Venous access and baseline imagingDocument the pre-existing pericardial space and reassess for thrombus before left-atrial instrumentation.
3. Transseptal punctureUse TEE or ICE plus fluoroscopy, confirm tenting at the planned site, cross safely, and anticoagulate according to protocol.
4. Sheath deliveryMaintain wire position, de-air meticulously, avoid scraping the atrial wall, and orient toward the intended axis.
5. Angiography and final sizingReconcile angiography with intraprocedural echo and pre-procedure CT rather than allowing one modality to dominate.
6. Controlled deploymentPreserve coaxiality and avoid aggressive advancement into thin distal tissue.
7. Release criteriaConfirm position, fixation, device-specific compression or conformation, acceptable seal, and stability without excessive traction.
8. Release and exitReconfirm position, mitral and pulmonary venous function, absence of new effusion, hemostasis, medication, and imaging plan.

Device families: mechanism matters

6. Complications: recognition and rescue

7. Evidence and landmark trials

The evidence has evolved from warfarin-controlled efficacy trials to contemporary device registries, randomized comparison with DOACs, head-to-head device trials, and ablation-adjacent strategies. Interpret each study by its comparator, device generation, post-implant regimen, operator era, and enrolled bleeding risk.

How to read the literature

• Separate procedural safety from long-term ischemic efficacy and bleeding benefit.
• Do not extrapolate first-generation complication rates directly to contemporary platforms.
• Count the post-implant antithrombotic regimen as part of the intervention.
• Examine how leak, device thrombus, cardiovascular death, and disabling stroke were adjudicated.
• Noninferiority does not mean equivalence for every component or patient phenotype.

8. Post-implant therapy and surveillance

Antithrombotic therapy must follow current device labeling, the evidence-supported regimen, and the patient’s bleeding and thrombotic risk. Contemporary strategies may use short-term anticoagulation plus aspirin or dual antiplatelet therapy in selected circumstances. No single regimen is universal.

Surveillance questions

• Is the device stable and in the intended position?
• Is there device-related thrombus?
• Is the appendage excluded, and what is the mechanism and magnitude of residual leak?
• Is there effusion or interaction with the mitral valve or pulmonary veins?
• Can therapy be de-escalated safely, or is treatment and repeat imaging required?

TEE or cardiac CT is commonly performed during early follow-up, with timing determined by labeling, regimen, protocol, and clinical events. New neurologic symptoms, embolism, unexplained dyspnea, chest pain, or bleeding should trigger earlier evaluation.

Selected foundational reading

1. SCAI/HRS expert consensus statement on transcatheter LAA closure.
2. PROTECT AF and PREVAIL randomized trials and long-term follow-up.
3. PRAGUE-17 randomized comparison with direct oral anticoagulation.
4. PINNACLE FLX prospective device evaluation.
5. Amulet IDE randomized head-to-head device trial.
6. OPTION randomized trial after atrial fibrillation ablation.
7. Current FDA labeling and manufacturer instructions for use for the implanted device.

Educational material for clinicians. It is not a substitute for device-specific training, current instructions for use, institutional protocols, multidisciplinary judgment, or individualized care. Evidence and labeling evolve; verify the current primary source before clinical application. Last educational review: September 2026.